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Metabolic neuropathophysiology underlying the prediabetic state may confer susceptibility to the adverse health
effects of ambient particulate matter <10 lm in diameter (PM10). The authors therefore examined whether impaired
glucose homeostasis modifies the effect of PM10 on heart rate variability in a stratified, random sample of 4,295
Women’s Health Initiative clinical trial participants, among whom electrocardiograms and fasting blood draws were
repeated at 3-year intervals from 1993 to 2004. In multilevel, mixed models weighted for sampling design and
adjusted for clinical and environmental covariables, PM10 exposure was inversely associated with heart rate vari-
ability. Inverse PM10–heart rate variability associations were strongest for the root mean square of successive
differences in normal-to-normal RR intervals (RMSSD). Among participants with impaired fasting glucose, there
were 8.3% (95% confidence interval: 13.9, 2.4) versus 0.6% (95% confidence interval: 2.4, 1.3), 8.4%
(95% confidence interval: 13.8, 2.7) versus 0.3% (95% confidence interval: 2.1, 1.6), and 4.3% (95%
confidence interval: 9.4, 1.0) versus 0.8% (95% confidence interval: 2.7, 1.0) decreases in the RMSSD
per 10-lg/m3 increase in PM10 at high versus low levels of insulin (P < 0.01), insulin resistance (P < 0.01), and
glucose (P ¼ 0.16), respectively. These associations were stronger among participants with diabetes and weaker
among those without diabetes or impaired fasting glucose. The findings suggest that insulin and insulin resistance
exacerbate the adverse effect of PM10 on cardiac autonomic control and thus risk of coronary heart disease among
nondiabetic, postmenopausal women with impaired fasting glucose.
diabetes mellitus; glucose; heart rate; insulin; particulate matter
Abbreviations: HOMA-IR, insulin resistance according to homeostatic model assessment; PM10, particulate matter <10 lm in
diameter; RMSSD, root mean square of successive differences in normal-to-normal RR intervals; SDNN, standard deviation of
normal-to-normal RR intervals; WHI, Women’s Health Initiative.
Measures of heart rate variability derived from short-term
electrocardiographic recordings are inversely associated
with risk of incident coronary heart disease (1–4). They
are also inversely associated with concentrations of ambient
particulate matter air pollution among persons with and
without diabetes (5, 6), implicating altered heart rate vari-
ability as a mechanism linking particulate matter exposures
to coronary heart disease events. It has been suggested that
the associations observed among nondiabetics may be at-
tributable to metabolic abnormalities related to insulin
resistance (7, 8). The metabolic neuropathophysiology com-
mon to both the prediabetic and diabetic states may therefore
confer susceptibility to the adverse autonomic and cardiovas-
cular effects of particulate matter, including reduced heart
rate variability.
Several studies have found evidence that indirectly sup-
ports this hypothesis (9–14), although most used adminis-
trative data to ascertain comorbid diabetes, an approach
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often characterized by insensitivity of disease detection,
resulting misclassification, and potential for bias in corre-
sponding measures of association, the direction and magni-
tude of which are difficult to evaluate adequately (15–17).
Prospective epidemiologic studies relying on more sensitive
methods of diabetes ascertainment have found compara-
tively little evidence supporting such particulate matter–
diabetes interactions. In the Adventist Health Study of Smog
(18) and the Harvard Six-Cities Study (19), for example, the
particulate matter–mortality association was similar when
stratifying by or excluding participants with diabetes. More-
over, in the Multiethnic Study of Atherosclerosis (20) and
the Women’s Health Initiative (WHI) observational study
(21), the associations among particulate matter, coronary
artery calcium, and coronary heart disease were stronger
among nondiabetic than diabetic participants.
Collectively, these findings suggest that the susceptibility
of persons with diabetes to the adverse effects of particulate
matter is rather uncertain, despite being biologically plau-
sible. Furthermore, modification of the particulate matter–
heart rate variability association by fasting glucose, insulin,
or insulin resistance in the nondiabetic state may be more
important from the public health perspective than modifica-
tion by diabetes per se, given the much larger population of
nondiabetic individuals with subclinical impairments of glu-
cose homeostasis who may be at risk of particulate matter-
related cardiovascular health problems because of these
metabolic abnormalities. However, the effects of subclinical
impairments in glucose homeostasis (22) on the particulate
matter–heart rate variability association among persons
without diabetes have not been evaluated.
We therefore examined them in the Environmental Epide-
miology of Arrhythmogenesis in the WHI, an ancillary study
of proarrhythmic mechanisms linking air pollution and car-
diovascular disease in the WHI clinical trials.
MATERIALS AND METHODS
Setting, design, and study population
The WHI clinical trials were designed to allow random-
ized, controlled evaluation of estrogen with or without pro-
gestin treatment, calcium/vitamin D supplementation, and
dietary modification on the risk of breast and colorectal
cancer, cardiovascular disease, and bone fractures (23). Be-
tween 1993 and 1998, the trials enrolled 68,132 postmeno-
pausal women aged 50–79 years who were followed at 1 of
75 US examination sites (including satellites, remote sites,
and their changes in location). Women were not eligible if
they had medical conditions predictive of survival time less
than 3 years, if they were known to have conditions incon-
sistent with study participation and adherence (e.g., alcohol
dependence), or if they were active participants in another
randomized, controlled trial. Women also were ineligible for
reasons of competing risk and safety. Each intervention arm
also incorporated specific eligibility criteria. Those who re-
mained eligible and interested were invited to follow-up
examinations at 1, 3, 6, and 9 years. Rigorous quality assur-
ance programs were in place through closeout (September
2004–March 2005).
Electrocardiograms
Centrally trained and officially certified technicians re-
corded resting, supine standard 12-lead electrocardiograms
at the baseline and year 3, 6, and 9 examinations (24). They
placed disposable silver/silver chloride electrodes on the pre-
cordium relative to standard anatomic landmarks using
the E-V6 Halfpoint Method (25), a HeartSquare device
(NovaHeart, Inc., Weston, Florida), and strictly standardized
protocols for positioning chest electrodes in women (26).
They digitally recorded electrocardiograms with participants
in the resting, supine position using MAC PC electrocardio-
graphs (Marquette Electronics, Milwaukee, Wisconsin). Upon
successful recording, they transmitted electrocardiograms
by telephone modem to the Epidemiological Cardiology
Research (EPICARE) Center (Division of Public Health
Sciences, School of Medicine, Wake Forest University,
Winston-Salem, North Carolina) for visual inspection, error/
missing lead detection, quality grading, and electronic reading
by the Marquette 12-SL program (GE Marquette, Milwaukee,
Wisconsin).
Heart rate variability measures
Electronic reading of the 10-second electrocardiograms
produced 3 measures that reflect influences of the autonomic
nervous system on the heart: 1) the median duration of the RR
interval across all 12 leads (RR, milliseconds); 2) the standard
deviation of all normal-to-normal RR intervals (SDNN, milli-
seconds) ¼ {[R(RRmean – RRj)2]/(n  1)}0.5; and 3) the root
mean square of successive differences in normal-to-normal
RR intervals (RMSSD, milliseconds) ¼ {[R(RRjþ1 – RRj)2]/
n}0.5 (27). The repeatability, accuracy, and predictive validity
of these short-term, time domain measures of heart rate vari-
ability have been described (28–30).
Addresses and geocodes
Participants’ addresses were collected at each visit and
updated at least biannually. All of the participants’ and ex-
amination site addresses in the contiguous United States
from baseline through follow-up were geocoded following
a standardized protocol by a single geocoding vendor se-
lected from 4 candidates on the basis of its accuracy (31,
32). The vendor assigned coordinates (latitudes, longitudes)
and unique census identifiers (2000 US Census Federal
Information Processing Standards codes) to >99% of the
addresses. Of these addresses, 91% were matched to specific
streets.
Air pollutant concentrations
All ambient criteria air pollutant concentration data re-
corded at monitors operating in the contiguous United States
during the study period were obtained from the US Envi-
ronmental Protection Agency Air Quality System (33). Data
recorded before and during 2004 were downloaded in
January 2005 and October 2006, respectively. The data
included the longitude and latitude of each monitor.
A semiautomated program was used to produce time
series of estimated daily mean (standard error) pollutant
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concentrations at each geocoded address from baseline
through closeout (34). The program relied on a spherical
model to perform national-scale, lognormal ordinary krig-
ing and the weighted least-squares method to estimate semi-
variograms (35–38). The program was run, and the default
(visually unadjusted) semivariograms were cross-validated
by using ArcView GIS, version 8.3, software (Environmental
Systems Research Institute, Inc. (ESRI), Redlands,
California) and its Geostatistical Analyst extension (39).
The validity of the model was evaluated by using standard
cross-validation statistics: the prediction error (predicted
minus measured pollutant concentration at each monitor site),
standardized prediction error (prediction error divided by
its estimated standard error), root mean square standardized
(standard deviation of standardized prediction error across
sites), root mean square prediction error (empirical standard
error based on the mean square of the predictions), and
mathematically calculated standard error. Observed values
of prediction error and standardized prediction error near 0,
values of root mean square standardized near 1, and the
similarity of root mean square prediction error and mathe-
matically calculated standard error provided evidence of
model validity (34, 40). Fifteen acute pollutant exposure
measures were computed by averaging the daily mean con-
centrations within overlapping 1-, 2-, and 3-day lag combi-
nations inside a 5-day exposure window ending on the
examination date.
Weather variables
All meteorologic data recorded at stations operating in
the contiguous United States during the study period were
obtained from the National Climatic Data Center. The data
included ambient temperature, dew point, and pressures, as
well as station longitudes, latitudes, and altitudes. Missing
sea level pressures were replaced with values computed
from station and altimeter pressures by using the station
altitude, ambient temperature, and US Standard Atmosphere
temperature profile (41, 42). The station-specific daily mean
temperature and sea level pressure were then computed at all
stations with at least 75% of consecutive, hourly measures
available for a given day. The daily mean temperature (C),
dew point (C), and pressure (kPa) were estimated at each
geocoded address from baseline to closeout by averaging
these daily means across all stations within 50 km, a distance
over which their station-to-station correlations exceed 0.90
(43). Thereafter, lagged weather variables were computed,
as described above for particulate matter <10 lm in
diameter (PM10).
Measures of glucose homeostasis
An examination site- and race-stratified, 6% random sam-
ple of women with a 6:1 overrepresentation of ethnic mi-
norities had fasting blood draws repeated at the year 3, 6,
and 9 examinations. Samples were processed, frozen at
70C, and then shipped to Medical Research Laboratories
(Highland Heights, Kentucky) for assay of plasma glucose
by the hexokinase method (44, 45) on a Hitachi 7474
analyzer (Boehringer Mannheim Diagnostics, Indianapolis,
Indiana) and serum insulin by a stepwise sandwich enzyme-
linked immunosorbent assay (46) on an ES 300 analyzer
(Boehringer Mannheim Diagnostics). Corresponding inter-
assay coefficients of variation were <2% and 3.2%–9.5%.
Insulin resistance according to homeostatic model assess-
ment (HOMA-IR) was computed (47, 48). Standard diag-
nostic criteria were used to define impaired fasting glucose
(glucose ¼ 100–125 mg/dL (5.6–6.9 mmol/L)) and diabetes
(antidiabetic medication use, glucose 126 mg/dL (7.0
mmol/L), or history) (49).
Other characteristics of participants
Self-reported education, medication use, health history
(see below), and a variety of other attributes were deter-
mined at each visit by standardized participant interview
and examination. Interim health events also were identified
via standardized medical record review and physician
adjudication, specifically: hypertension by antihypertensive
medication use, systolic blood pressure 140 mm Hg,
diastolic blood pressure 90 mm Hg, or history; body
mass index (weight (kg)/height (m)2); total energy expendi-
ture (kcal/kg 3 week) based on the type, frequency, and
duration of recreational physical activity (50); hypercholes-
terolemia by antihyperlipidemic medication use or history;
smoking as current, former, or never; chronic lung disease
by history of asthma, emphysema, or lung cancer; coronary
heart disease by antianginal medication use, history of
angina or myocardial infarction, or medical record review/
adjudication; revascularization by history of coronary artery
angioplasty, stent or bypass, or medical record review/
adjudication; and congestive heart failure by cardiac glyco-
side and diuretic use, history, or medical record review/
adjudication.
Exclusions
Of the 68,132 participants examined between 1993 and
2004, 4,376 (6.4%) with sampled glucose or insulin concen-
trations and addresses in the contiguous 48 US states were
included. Of these 4,376 participants, 81 (1.9%) were ex-
cluded because they had conditions that affect the availabil-
ity or accuracy of heart rate variability measures: missing,
duplicate baseline, nonroutine, fourth or later electrocardio-
grams; poor electrocardiogram quality grades; <5 or 50%
normal-to-normal RR intervals; atrioventricular conduction
defects; electronic pacers; frequent premature ventricular
beats; arrhythmias; or antiarrhythmic medication use. All
analyses were conducted among the remaining 4,295 par-
ticipants, 50% of whom had 3, 32% had 2, and 18% had
only 1 examination during the study period.
Statistical analysis
Analyses relied on a 3-level, random-effects model of the
heart rate variability–PM10 association in which i, j, and k
denote the ith examination (level 1) of the jth participant
(level 2) in the kth examination site (level 3). The basic
model is given by
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where Yijk denotes a log-transformed heart rate variability
measure, b1–b4 denote fixed effects parameter estimates,
and both b1–b3 and e denote random effects. In this model,
b1 is the intercept, Pijk is PM10 (lg/m
3), tijk is an interval-
scale measure of time (year) since baseline, and Cijk is a vec-
tor of covariates. The terms (b1k
(3), b2k
(3)) ~ N(0,G(3)) are
a random intercept and a random slope for PM10 at level 3,
(b1jk
(2), b2jk
(2)) ~ N(0,G(2)) are a random intercept and a ran-
dom slope for time at level 2, and eijk
(1) ~ N(0,r2) is the
random error at level 1. The parenthetical superscripts in-
dicate the levels within which random effects varied and
were assumed independent.
To compensate for bias associated with unequal probabil-
ities of sampling across examination sites and race, site- and
race-specific sampling weights were empirically calculated
from participant counts at each examination, participant
weights as inverse probabilities of including participants
within site-race strata, and examination weights as inverse
response probabilities at each examination. The MULTILEV
procedure in LISREL, version 8.8, software (Scientific
Software International, Inc., Lincolnwood, Illinois) was
used to incorporate these weights in the above models,
thereby allowing inferences to the dynamic population of
WHI clinical trial participants from which the site- and
race-stratified, 6% random sample was drawn. The procedure
proportionally scaled the participant weights to sum to
participant sample sizes within site-race strata and examina-
tion weights to sum to number of examinations per
participant, a process that decreases bias in random-effects
parameters and improves efficiency (51, 52). To adjust for
attrition, the models were rerun after multiplying examina-
tion weights by inverse participant response probabilities
at follow-up examinations estimated in weighted logistic
regression models, including their demographic and clinical
characteristics at prior examinations.
Models were also run in subgroups of participants with
diabetes, impaired fasting glucose, and normal fasting glu-
cose. For simplicity, effect measure modification (signifi-
cance of the PM10 3 insulin, PM10 3 HOMA-IR, and
PM10 3 glucose interactions) was tested within these sub-
groups by using subgroup-specific indicators for high versus
low insulin, HOMA-IR, and glucose. Findings based on the
dichotomization of these variables at the 50th–90th percen-
tiles were compared to determine their sensitivity to use of
arbitrarily chosen thresholds.
To control for potential confounding by season, day of
week, time of day, health, and weather in analyses of the
particulate matter–heart rate variability association, tempo-
ral, sociodemographic, clinical, and weather covariables
were added to the models. Final models included the
interval-scale weather variables mentioned above. Differen-
ces in findings based on final models and those containing
single (or pairs of) weather variables were negligible. Final
models also included 3 indicator variables for the 4 seasons:
spring (i.e., March, April, or May), summer, fall, and winter.
The indicator variable model was compared with models
including 2 or 4 harmonic seasonal terms: sin(2Pjt/366)
and cos(2Pjt/366), where j ¼ (1) or j ¼ (1, 2) and t ¼
(examination day, i.e., 1, 2, 3, . . ., or 366). Goodness of
fit based on the Akaike Information Criterion was greatest
for the indicator variable model, leading to its adoption.
Interval-scale covariables were centered, and a deviation
from means coding scheme for categorical covariables was
used to simplify interpretation. By convention, the resulting
estimates of association are reported as percent changes in
heart rate variability per 10-lg/m3 increase in PM10
concentration.
Modeling was preceded by estimation of examination-
specific summary statistics weighted for the sampling and
response probabilities described above by using SUDAAN,
version 9.0.1, software (SUDAAN Statistical Software
Center, Research Triangle Park, North Carolina). The
weighting method scaled participant contributions to the
summary statistics in a manner inversely proportional to
these probabilities, again allowing inference to the sampling
frame from which the site- and race-stratified, 6:1 minority
oversample was drawn. Combining participants examined
in Iowa City and Davenport, Iowa, in Jacksonville and
Gainesville, Florida, and at sites with an affiliated remote
site and/or change in location allowed us to avoid analytical
problems associated with sparse data within site-race strata
at later examinations.
RESULTS
Participant, monitor, and examination site locations are
illustrated in Web Figure 1. (These locations are shown in
the first of 2 supplementary figures; each is referred to as
‘‘Web Figure’’ in the text and is posted on the Journal’s
website (http://aje.oxfordjournals.org/).) Most participants
were born in the 1930s, white, and not college educated
(Table 1). They were examined less in winter, on weekends,
and late in the day. Their coronary heart disease risk factor
burden was substantial at examination 1, when 28% were
randomized to estrogen with or without progestin treatment,
26% to calcium/vitamin D supplementation, and 25% to di-
etary modification. By examination 3, participants had aged
an average of 5 years; they were being examined earlier in the
year, week, and day; and they were more likely to have
a major coronary heart disease risk factor or coronary heart
disease itself. At examination 1, the mean values for RR,
SDNN, and RMSSD were lower among participants with
diabetes (868, 16, 19 milliseconds) than among those with
impaired fasting glucose (915, 20, 21 milliseconds) or normal
fasting glucose (947, 21, 22 milliseconds). Across examina-
tions, RR increased, but SDNN and RMSSD decreased
(Table 2). The PM10 concentration, temperature, and dew
point averaged over lag 0 and 1 (lag0-1) peaked in the summer
to fall, while barometric pressure peaked in the winter (Web
Figure 2). The mean values of these variables were compar-
atively stable across examinations (Table 2), a period during
which lag0-1 PM10 remained approximately 18% of the cur-
rent, 24-hour standard (150 lg/m3) (53).
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Table 1. Characteristics of the Participants by Examination, the Environmental Epidemiology of Arrhythmogenesis
in the Women’s Health Initiative, 1993–2004
Characteristic







Age, years 64 (0.1) 67 (0.2) 69 (0.2)
Race/ethnicity
White/non-Hispanic 83 84 85
Black/African American 10 9 8
Hispanic/Latino 4 4 4
Other 3 3 2
Education less than college graduate 64 63 62
Examination season
Spring 27 27 28
Summer 25 27 28
Fall 24 24 23
Winter 23 23 21
Examination day
Monday 18 21 22
Tuesday 25 23 23
Wednesday 23 20 23
Thursday 19 20 20
Friday 12 14 12
Saturday–Sunday 3 2 1
Examination time of day 12:10 (00:03) 10:14 (00:03) 9:54 (00:02)
Diabetesb 9 10 12
Impaired fasting glucoseb 23 21 26
Normal fasting glucoseb 68 69 62
Glucose, mg/dLc 100 (0.5) 99 (0.5) 101 (0.6)
Insulin, mIU/Lc 12 (0.1) 12 (0.2) 10 (0.2)
HOMA-IRc 3.0 (0.1) 3.2 (0.1) 2.7 (0.1)
Hypertension 44 47 54
SBP/DBP, mm Hg 128/76 (0.4/0.2) 126/73 (0.4/0.2) 125/71 (0.4/0.2)
b-Blocker use 8 11 16
Body mass index, kg/m2 29 (0.1) 29 (0.1) 29 (0.2)
Total energy expenditure, kcal/kg 3 weekd 11 (0.3) 11 (0.3) 11 (0.3)
Hypercholesterolemia 12 17 26
Current smoker 9 6 5
Chronic lung disease 10 11 10
Coronary heart disease 6 7 9
Revascularization 1 2 3
Congestive heart failure 1 2 2
Abbreviations: HOMA-IR, insulin resistance according to homeostatic model assessment; SBP/DBP, systolic/
diastolic blood pressure; SE, standard error.
a Mean (SE) and percent weighted for sampling design and attrition. Percentages may not sum to 100 because of
rounding.
b ‘‘Diabetes’’ is defined as antidiabetic medication use, a fasting glucose level of 126 mg/dL (7.0 mmol/L), or
history; ‘‘impaired fasting glucose’’ is a glucose level of 100–125 mg/dL (5.6–6.9 mmol/L); and ‘‘normal fasting
glucose’’ is a fasting glucose level of 99 mg/dL (5.5 mmol/L).
c The 90th percentiles of glucose, insulin, and HOMA-IR were 116 mg/dL, 20 mIU/L , and 5.3 (examination 1), 117
mg/dL, 21 mIU/L, and 5.7 (examination 2), and 121mg/dL, 18 mIU/L , and 5.1 (examination 3), respectively.
d Missing 11% and 5% of values at examinations 1 and 2. For all other variables, 1% of values were missing.
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Log-transformed heart rate variability measures were in-
versely associated with PM10 concentrations, more strongly
so at shorter lags: The unadjusted percent change per 10-lg/
m3 increase in PM10 at lags 0–3 was: 0.9, 0.9, 0.4, and
0.0 for RMSSD; 0.7, 0.6, 0.2, and 0.1 for SDNN; and
0.2, 0.0, 0.1, and 0.1 for RR, respectively. Lag0-1 PM10
concentrations also were weakly and inversely associated
with heart rate variability in unadjusted models. P values
associated with adding terms for the lag0-1 PM10 3 (normal,
impaired fasting glucose, diabetes) interaction to the unad-
justed models were 0.304 for RMSSD, 0.457 for SDNN, and
0.983 for RR. Overlapping 95% confidence intervals asso-
ciated with the percent change in RMSSD, SDNN, and RR
per 10-lg/m3 increase in PM10 also were observed after
stratification of the unadjusted models (Table 3). Adjust-
ment of the stratified models strengthened the inverse par-
ticulate matter–RMSSD and particulate matter–SDNN
associations among the diabetes and impaired fasting glu-
cose subgroups.
Within these subgroups, the inverse associations tended
to be significantly stronger at high (>90th percentile) versus
low levels of insulin and HOMA-IR (Table 4). Differences
persisted when insulin and HOMA-IR were dichotomized at
the 70th or 50th percentile. Within the diabetes subgroup,
the effects of further adjustment for use of antidiabetic med-
ications were negligible. Findings based on models also
adjusting for attrition, restricting to single cross-sectional
examinations or the 50% of participants with all 3 exami-
nations, excluding outlying lag0-1 PM10 concentrations, and
controlling for randomization status, were comparable.
DISCUSSION
Among US women aged 60 years, the prevalence of
diabetes was approximately 19% between 1999 and 2002
(22). This value represented only one-third of the combined
total burden of diabetes and impaired fasting glucose in this
segment of the US population at the time. Indeed, of the
remaining majority of women aged 60 years that did not
have diagnosed or undiagnosed diabetes, fully 34% had
impaired fasting glucose, a common condition previously
identified as an important risk marker for cardiovascular
disease (54).
With the cardiovascular implications of impaired fasting
glucose and decreased heart rate variability (1–4) in mind,
the present study examined the effects of common impair-
ments in glucose homeostasis on the PM10–heart rate vari-
ability association. It did so among a geographically
heterogeneous, site- and race-stratified, randomly selected
minority oversample of postmenopausal women enrolled in
the WHI clinical trials. It focused on 3 subgroups of the
women who were, on average, in their mid- to late sixties
at the time of their examinations: those with diabetes, im-
paired fasting glucose, and normal fasting glucose.
The study found that, in women with diabetes, there was
a much stronger inverse particulate matter–RMSSD associ-
ation when either insulin or HOMA-IR was high. The di-
rection of the association in this subgroup was fairly
consistent across heart rate variability measures, but its
magnitude tended to be greater for both RMSSD and SDNN
than for RR. Perhaps more important, however, were the
persistence of the PM10–heart rate variability associations
in women with impaired fasting glucose and, by compari-
son, its striking attenuation in those women with neither
diabetes nor impaired fasting glucose.
The persistence and then attenuation of the PM10–heart
rate variability association across the spectrum of glucose
homeostasis examined in this setting are consistent with find-
ings in men with and without diabetes (9), but they also
extend to the relatively mild forms of hyperinsulinemia and
insulin resistance that characterize the much larger popula-
tion of nondiabetic US women with impaired fasting glucose.
The extensions imply that the metabolic neuropathophysiology
underlying the prediabetic state may confer susceptibility to
the adverse autonomic effects of particulate matter on the
heart. Indeed, the findings presented here are consistent with
a neuropathophysiologic model linking prediabetic metabolic
abnormalities including hyperinsulinemia to altered autonomic
Table 2. Heart Rate Variability and Environmental Measures by Examination, the Environmental Epidemiology of Arrhythmogenesis in the


























RR, milliseconds 932 (2.8) 761 1,114 936 (3.0) 763 1,118 942 (3.4) 773 1,111
SDNN, milliseconds 20 (0.4) 7 37 20 (0.4) 6 36 19 (0.4) 6 34
RMSSD, milliseconds 22 (0.5) 7 40 21 (0.5) 6 39 21 (0.6) 7 38
PM10, lg/m
3b 28 (0.2) 16 42 27 (0.2) 16 42 27 (0.3) 16 41
Temperature, Cb 14 (0.2) 1 25 14 (0.2) 1 24 14 (0.2) 1 25
Dew point, Cb 8 (0.2) 5 19 8 (0.2) 5 19 8 (0.2) 5 19
Barometric pressure, kPab 102 (0.01) 101 102 102 (0.01) 101 102 102 (0.01) 101 102
Abbreviations: PM10, particulate matter of <10 lm in diameter; RMSSD, root mean square of successive differences in normal-to-normal RR
intervals; RR, median RR interval across all 12 leads; SDNN, standard deviation of normal-to-normal RR intervals; SE, standard error.
a Summary statistics were weighted for sampling design and attrition.
b Daily means were averaged over a 2-day period ending on the examination date (lag01).
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nervous system activity, the latter manifest as a reduction in
heart rate variability (7, 8) and exacerbated by the previously
documented effects of particulate matter (5, 6). Because re-
duced heart rate variability is, in turn, associated with risk of
incident coronary heart disease (1–4), the clinical and public
health implications of these findings are potentially important.
However, autonomic processes are not solely accountable
for the adverse effects of particulate matter on the heart.
Recent findings suggest otherwise: Hemostatic, endothelial,
inflammatory, and oxidative mechanisms of disease, as
well as others not examined by this study, also have been
implicated in the cardiovascular effects of particulate matter
(55–59).
The extension nevertheless offers insight into the discrep-
ant literature regarding the putative particulate matter–
diabetes interaction, the existence of which is supported
by some studies (10–14) but not by others (18–21). If the
present findings can be confirmed, the confirmation would
suggest that the observed inconsistency of the biologically
plausible particulate matter–diabetes interaction may relate
more to the residual effects of insulin and insulin resistance
in nondiabetic persons with impaired fasting glucose than
to the absence of effect measure modification by diabetes,
per se. Such a conclusion would nonetheless have to be
tempered by the possibility that, in the presence of strong
effects of diabetes on, for example, heart rate variability,
relatively weak environmental effects of particulate matter
may be quite challenging to measure, particularly in admin-
istrative data sets (15–17).
This study has several limitations that may affect inter-
pretation of its findings. First, it is an ancillary study of
participants in the WHI clinical trials. As such, women in it
were randomized to estrogen with or without progestin
treatment, calcium/vitamin D supplementation, and/or
dietary modification. Although women were randomized,
these exposures may have affected the measures of both
heart rate variability and glucose homeostasis. Second,
heart rate variability was measured from resting, standard
12-lead electrocardiograms that were only 10 seconds in
duration. Such measures reflect heart rate variation in the
time domain and over the short term. Third, PM10 was not
measured in the personal breathing space of participants.
Instead, it was spatially interpolated at each participant’s
geocoded address, raising questions about its validity.
Finally, there was considerable attrition of the examination
site- and race-stratified minority oversample. In the face
Table 3. Percent Change in Heart Rate Variability per 10-lg/m3 Increase in lag0-1 PM10 Concentration, the
Environmental Epidemiology of Arrhythmogenesis in the Women’s Health Initiative, 1993–2004





Glucoseb (n 5 1,559c)
Normal Fasting














Model 1 0.1 3.4, 3.3 0.7 2.3, 1.0 1.9 3.3, 0.5
Model 2 0.7 3.9, 2.7 0.6 2.2, 1.0 1.9 3.3, 0.5
Model 3 3.7 6.8, 0.5 1.2 3.0, 0.7 2.1 3.8, 0.5
SDNN
Model 1 0.3 3.3, 2.9 0.3 1.7, 1.3 1.4 2.8, 0.0
Model 2 0.6 3.7, 2.6 0.3 1.8, 1.2 1.3 2.6, 0.1
Model 3 2.5 5.3, 0.5 0.8 2.4, 0.8 1.1 2.6, 0.5
RR
Model 1 0.4 1.0, 0.3 0.1 0.5, 0.3 0.2 0.5, 0.0
Model 2 0.4 1.0, 0.2 0.1 0.5, 0.3 0.2 0.5, 0.0
Model 3 1.0 1.7, 0.3 0.1 0.3, 0.6 0.5 0.7, 0.2
Abbreviations: PM10, particulate matter of <10 lm in diameter; RMSSD, root mean square of successive differ-
ences in normal-to-normal RR intervals; RR, median RR interval across all 12 leads; SDNN, standard deviation of
normal-to-normal RR intervals.
a Model 1, unadjusted; model 2, adjusted for age (year) and race/ethnicity; model 3, also adjusted for education,
time of day (minutes), day of week, season, bodymass index (kg/m2), hypertension, systolic blood pressure (mmHg),
b-blocker use, total energy expenditure (kcal/kg 3 weeks), current smoker status, chronic lung disease, hypercho-
lesterolemia, coronary heart disease, revascularization, congestive heart failure, lag0-1 temperature (C), dew point
(C), and barometric pressure (kPa). Indicators were used to represent the categorical variables in Table 1.
b ‘‘Diabetes’’ is defined as antidiabetic medication use, a fasting glucose level of 126 mg/dL (7.0 mmol/L), or
history; ‘‘impaired fasting glucose’’ is a glucose level of 100–125 mg/dL (5.6–6.9 mmol/L); and ‘‘normal fasting
glucose’’ is a fasting glucose level of 99 mg/dL (5.5 mmol/L).
c Unweighted number of participants with diabetes, impaired fasting glucose, or normal fasting glucose at visit 1, 2,
or 3.
d Percent change weighted for sampling design.
Heart Rate, Air Pollution, and Glucose Homeostasis 699
Am J Epidemiol 2009;169:693–703
of these limitations, the study took several precautions. It
carefully established both the reliability and accuracy of its
heart rate variability measures (28), geocodes (31), and
spatial interpolations (34, 40) relative to criterion stand-
ards; it documented modest effects of exposure measure-
ment error in the latter on particulate matter–coronary
heart disease and particulate matter–RR associations (31,
60, 61); and it adjusted effect sizes for randomization
Table 4. Percent Change in Heart Rate Variability per 10-lg/m3 Increase in lag0-1 PM10 Concentration, at High and Low Measures of Glucose
Homeostasis, the Environmental Epidemiology of Arrhythmogenesis in the Women’s Health Initiative, 1993–2004a






Glucoseb (n 5 1,559c)
Normal Fasting






















High 16.9 23.4, 9.9 <0.01 8.3 13.9, 2.4 <0.01 0.1 4.1, 4.0 1.00
Low 1.9 5.1, 1.5 0.6 2.4, 1.3 2.3 4.0, 0.6
HOMA-IR
High 24.5 33.3, 14.6 <0.001 8.4 13.8, 2.7 <0.01 1.3 5.3, 2.9 1.00
Low 0.3 2.9, 3.7 0.3 2.1, 1.6 2.2 3.9, 0.4
Glucose
High 15.7 25.7, 4.4 <0.01 4.3 9.4, 1.0 0.16 0.8 4.3, 2.9 0.33
Low 1.8 5.0, 1.4 0.8 2.7, 1.0 2.3 4.0, 0.5
SDNN
Insulin
High 16.8 23.5, 9.5 <0.01 7.4 12.9, 1.6 0.02 1.8 2.1, 5.9 0.36
Low 0.6 3.5, 2.5 0.1 1.6, 1.4 1.3 2.9, 0.4
HOMA-IR
High 21.5 29.4, 12.7 <0.001 5.4 11.0, 0.5 0.08 1.8 2.0, 5.7 0.37
Low 0.8 2.1, 3.9 0.1 1.6, 1.3 1.3 2.9, 0.4
Glucose
High 11.8 20.8, 1.7 0.04 0.4 5.1, 4.5 0.89 0.3 4.1, 3.7 0.66
Low 1.1 4.0, 1.8 0.9 2.4, 0.7 1.2 2.7, 0.5
RR
Insulin
High 2.4 4.2, 0.5 <0.01 0.7 1.9, 0.4 0.16 0.4 1.1, 0.3 0.88
Low 0.8 1.5, 0.1 0.3 0.1, 0.7 0.4 0.8, 0.1
HOMA-IR
High 3.2 5.7, 0.6 <0.001 1.1 2.2, 0.0 0.02 0.5 1.2, 0.2 0.92
Low 0.7 1.4, 0.0 0.4 0.0, 0.8 0.4 0.8, 0.1
Glucose
High 3.0 5.4, 0.6 <0.001 0.3 1.2, 0.6 0.42 1.6 2.2, 0.9 <0.01
Low 0.7 1.4, 0.0 0.2 0.2, 0.6 0.3 0.6, 0.0
Abbreviations: HOMA-IR, insulin resistance according to homeostatic model assessment; PM10, particulate matter of <10 lm in diameter;
RMSSD, root mean square of successive differences in normal-to-normal RR intervals; RR, median RR interval across all 12 leads; SDNN,
standard deviation of normal-to-normal RR intervals.
a High values of insulin, HOMA-IR, and glucose defined as >90th percentile.
b ‘‘Diabetes’’ is defined as antidiabetic medication use, a fasting glucose level of126 mg/dL (7.0 mmol/L), or history; ‘‘impaired fasting glucose’’
is a glucose level of 100–125 mg/dL (5.6–6.9 mmol/L); and ‘‘normal fasting glucose’’ is a fasting glucose level of 99 mg/dL (5.5 mmol/L).
c Unweighted number of participants with diabetes, impaired fasting glucose, or normal fasting glucose at visit 1, 2, or 3.
d Weighted for sampling design and adjusted for age (year), race/ethnicity, education, time of day (minutes), day of week, season, body mass
index (kg/m2), hypertension, systolic blood pressure (mm Hg), b-blocker use, total energy expenditure (kcal/kg 3 weeks), current smoker status,
chronic lung disease, hypercholesterolemia, coronary heart disease, revascularization, congestive heart failure, lag0-1 temperature (C), dew point
(C), and barometric pressure (kPa). Indicators were used to represent the categorical variables in Table 1.
e P value for the test of the PM10 3 insulin, PM10 3 HOMA-IR, or PM10 3 glucose interaction.
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status and participant attrition, noting only small changes
as a result of adjustment.
Despite such reassurance, participants with diabetes had
both the lowest mean baseline heart rate variability mea-
sures and the highest particulate matter-related decreases
in heart rate variability across examinations, while those
with normal fasting glucose had both the highest mean base-
line heart rate variability measures and the lowest particulate
matter-related decreases in heart rate variability across ex-
aminations. Although these observations suggest that sub-
group differences in baseline heart rate variability may have
affected the strength of the particulate matter–heart rate
variability association, they are inconsistent with regression
to the mean, in which selection of participants from a popu-
lation on the basis of a baseline measure is associated with
increased proximity of subsequent measures to the popula-
tion mean, not greater divergence from it. The interactions
observed in this context are therefore unlikely to be simple
reflections of subgroup differences in baseline heart rate
variability that have been misattributed to the effects of PM10.
We therefore conclude that insulin and insulin resistance
increase susceptibility to the adverse effect of ambient par-
ticulate matter air pollution on cardiac autonomic control
among nondiabetic, postmenopausal women with impaired
fasting glucose. Such increases in susceptibility may, in
turn, influence the risk of coronary heart disease among
persons with this endocrinologic condition.
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